The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 10 rounds in the feed, most often at Series A and in Biotech.
Corporationlogosfund.comRounds from 2022-01-06 to 2026-09-30
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Tangent Robotics A company spun off from Columbia University to develop the fine motor skill layer for robotic manipulation | Pre-seed Verified against 4 of 27 sources | $4.5M | 2026-09-30 | [ PART ] |
Rune A data center technology startup | Series A Verified against 4 of 7 sources |
| $40M |
| 2026-09-16 |
| [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $250M | 2026-01-12 | [ PART ] |
Diagonal Therapeutics They develop innovative clustering antibodies for the treatment of genetic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-01-08 | [ PART ] |
Expedition Therapeutics Expedition Therapeutics develops novel treatments for inflammatory and respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD). | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2025-10-09 | [ PART ] |
Verdiva Bio Verdiva Bio develops next-generation medicines aimed at treating obesity and cardiometabolic diseases. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $411M | 2025-01-09 | [ PART ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $400M | 2024-03-21 | [ PART ] |
Odyssey Odyssey Therapeutics develops innovative therapies aimed at transforming the treatment of autoimmune and inflammatory diseases for patients. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $168M | 2022-10-13 | [ PART ] |
Triana Biomedicines Trianabio sells novel biopharmaceutical therapeutics focused on utilizing molecular glues to treat previously undruggable diseases, primarily targeting cancer. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2022-04-06 | [ PART ] |
BFREE Africa’s leading ethical credit manager | Pre-A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $1.7M | 2022-01-06 | [ PART ] |